Inhibitors of the Candida albicans major facilitator superfamily transporter Mdr1p responsible for fluconazole resistance

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Keniya, Mikhail V ^a   Fleischer, Edmond ^b   Klinger, Anette ^b   Cannon, Richard D ^a   Monk, Brian C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Building E512   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DIMETHYL 1H PYRAZOL 1 YL) 4 (PHENYLAMINO)CYCLOBUT 3 ENE 1,2 DIONE; 3 (BENZYLAMINO) 4 (3,5 DIMETHYL 1 H PYRAZOL 1 YL)CYCLOBUT 3 ENE 1,2 DIONE; 3 (BENZYLAMINO) 4 [[1,3,3 TRIMETHYL 2,3 DIHYDRO 1H INDOL 2 YLIDENE]METHYL]CYCLOBUT 3 ENE 1,2 DIONE; 3 (PHENYLAMINO) 4 [[1,3,3 TRIMETHYL 2,3 DIHYDRO 1H INDOL 2 YLIDENE]METHYL]CYCLOBUT 3 ENE 1,2 DIONE; 3 (PHENYLSUFANYL) 4 [[1,3,3 TRIMETHYL 2,3 DIHYDRO 1H INDOL 2 YLIDENE]METHYL]CYCLOBUT 3 ENE 1,2 DIONE; 3 CHLORO 4 [[1,3,3 TRIMETHYL 2,3 DIHYDRO 1H INDOL 2 YLIDENE]METHYL]CYCLOBUT 3 ENE 1,2 DIONE; 3 [[4 CHLOROPHENYL]AMINO] 4 [[1,3,3 TRIMETHYL 2,3 DIHYDRO 1H INDOL 2 YLIDENE]METHYL]CYCLOBUT 3 ENE 1,2 DIONE; ABC TRANSPORTER; ANTIFUNGAL AGENT; CYCLOBUTENE DIONE; FLUCONAZOLE; FUNGAL PROTEIN; HYGROMYCIN B; MAJOR FACILITATOR SUPERFAMILY TRANSPORTER; MDR1P PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; [[4 METHYLPHENYL]AMINO] 4 [[1,3,3 TRIMETHYL 2,3 DIHYDRO 1H INDOL 2 YLIDENE]METHYL]CYCLOBUT 3 ENE 1,2 DIONE; CARRIER PROTEIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CELL MEMBRANE; CHEMOSENSITIZATION; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DRUG SOLUBILITY; DRUG STRUCTURE; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PH; PROTEIN EXPRESSION; PROTEIN FAMILY; SACCHAROMYCES CEREVISIAE; SYNTHESIS; YEAST; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; MICROBIAL SENSITIVITY TEST;

CANDIDA ALBICANS; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CANDIDA ALBICANS; DRUG SYNERGISM; FLUCONAZOLE; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS;

EID: 84929095175     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126350     Document Type: Article

References (38)

1. Akins RA (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43: 285-318. PMID: 16110776
2. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, et al. (2009) Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 22: 291-321. doi: 10.1128/CMR.00051-08 PMID: 19366916
3. Holmes AR, Lin YH, Niimi K, Lamping E, Keniya M, Niimi M, et al. (2008) ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob Agents Chemother 52: 3851-3862. doi: 10.1128/AAC.00463-08 PMID: 18710914
4. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, et al. (2001) Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45: 2676-2684. PMID: 11557454
5. Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, et al. (1998) Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 42: 2932-2937. PMID: 9797228
6. White TC (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41: 1482-1487. PMID: 9210670
7. White TC, Holleman S, Dy F, Mirels LF, Stevens DA (2002) Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 46: 1704-1713. PMID: 12019079
8. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J (1998) Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 42: 3065-3072. PMID: 9835492
9. Fling ME, Kopf J, Tamarkin A, Gorman JA, Smith HA, Koltin Y (1991) Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 227: 318-329. PMID: 2062311
10. Becker JM, Henry LK, Jiang W, Koltin Y (1995) Reduced virulence of Candida albicans mutants affected in multidrug resistance. Infection and immunity 63: 4515-4518. PMID: 7591094
11. Lohberger A, Coste AT, Sanglard D (2014) Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence. Eukaryot Cell 13: 127-142. doi: 10.1128/EC.00245- 13 PMID: 24243794
12. Dunkel N, Blass J, Rogers PD, Morschhauser J (2008) Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazoleresistant Candida albicans strains. Mol Microbiol 69: 827-840. doi: 10.1111/j.1365-2958.2008.06309.x PMID: 18577180
13. Morschhauser J (2010) Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 47: 94-106. doi: 10.1016/j.fgb.2009.08.002 PMID: 19665571
14. Hiller D, Sanglard D, Morschhauser J (2006) Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida albicans. Antimicrob Agents Chemother 50: 1365-1371. PMID: 16569853
15. Cheng S, Clancy CJ, Nguyen KT, Clapp W, Nguyen MH (2007) A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole. Antimicrob Agents Chemother 51: 1855-1858. PMID: 17325226
16. Niimi M, Niimi K, Takano Y, Holmes AR, Fischer FJ, Uehara Y, et al. (2004) Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. Journal of Antimicrobial Chemotherapy 54: 999-1006. PMID: 15486081
17. Monk BC, Niimi K, Lin S, Knight A, Kardos TB, Cannon RD, et al. (2005) Surface-active fungicidal Dpeptide inhibitors of the plasma membrane proton pump that block azole resistance. Antimicrobial Agents & Chemotherapy 49: 57-70.
18. Niimi K, Harding DR, Holmes AR, Lamping E, Niimi M, Tyndall JD, et al. (2012) Specific interactions between the Candida albicans ABC transporter Cdr1p ectodomain and a D-octapeptide derivative inhibitor. Mol Microbiol 85: 747-767. doi: 10.1111/j.1365-2958.2012.08140.x PMID: 22788839
19. Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K (2003) Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int J Antimicrob Agents 22: 291-300. PMID: 13678837
20. Sharma M, Manoharlal R, Shukla S, Puri N, Prasad T, Ambudkar SV, et al. (2009) Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob Agents Chemother 53: 3256-3265. doi: 10.1128/AAC.01497-08 PMID: 19470507
21. Ricardo E, Costa-de-Oliveira S, Dias AS, Guerra J, Rodrigues AG, Pina-Vaz C (2009) Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes. FEMS Yeast Res 9: 618-625. doi: 10.1111/j.1567-1364.2009.00504.x PMID: 19416368
22. Maurya IK, Thota CK, Verma SD, Sharma J, Rawal MK, Ravikumar B, et al. (2013) Rationally designed transmembrane peptide mimics of the multidrug transporter protein Cdr1 act as antagonists to selectively block drug efflux and chemosensitize azole-resistant clinical isolates of Candida albicans. The Journal of biological chemistry 288: 16775-16787. doi: 10.1074/jbc.M113.467159 PMID: 23592791
23. Diwischek F, Morschhauser J, Holzgrabe U (2009) Cerulenin analogues as inhibitors of efflux pumps in drug-resistant Candida albicans. Arch Pharm (Weinheim) 342: 150-164. doi: 10.1002/ardp. 200800160 PMID: 19253321
24. Holmes AR, Keniya MV, Ivnitski-Steele I, Monk BC, Lamping E, Sklar LA, et al. (2012) The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrob Agents Chemother 56: 1508-1515. doi: 10.1128/AAC.05706-11 PMID: 22203607
25. Ivnitski-Steele I, Holmes AR, Lamping E, Monk BC, Cannon RD, Sklar LA (2009) Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Analytical biochemistry 394: 87-91. doi: 10.1016/j.ab.2009.07.001 PMID: 19577533
26. Lamping E, Monk BC, Niimi K, Holmes AR, Tsao S, Tanabe K, et al. (2007) Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell 6: 1150-1165. PMID: 17513564
27. Marr KA, Lyons CN, Ha K, Rustad TR, White TC (2001) Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 45: 52-59. PMID: 11120944
28. Kelly R, Miller SM, Kurtz MB, Kirsch DR (1987) Directed mutagenesis in Candida albicans: one-step gene disruption to isolate ura3 mutants. Mol Cell Biol 7: 199-208. PMID: 3031459
29. Albertson GD, Niimi M, Cannon RD, Jenkinson HF (1996) Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 40: 2835-2841. PMID: 9124851
30. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D (2000) Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrobial Agents & Chemotherapy 44: 2373-2381.
31. Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52: 1. PMID: 12805255
32. Niimi K, Harding DR, Parshot R, King A, Lun DJ, Decottignies A, et al. (2004) Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother 48: 1256-1271. PMID: 15047528
33. Stevens DA, Espiritu M, Parmar R (2004) Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 48: 3407-3411. PMID: 15328104
34. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP (2007) Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother 51: 2257-2259. PMID: 17438060
35. Richards TS, Oliver BG, White TC (2008) Micafungin activity against Candida albicans with diverse azole resistance phenotypes. J Antimicrob Chemother 62: 349-355. doi: 10.1093/jac/dkn156 PMID: 18436555
36. McCusker JH, Perlin DS, Haber JE (1987) Pleiotropic plasma membrane ATPase mutations of Saccharomyces cerevisiae. Mol Cell Biol 7: 4082-4088. PMID: 2963211
37. Milewski S, Mignini F, Prasad R, Borowski E (2001) Unusual susceptibility of a multidrug-resistant yeast strain to peptidic antifungals. Antimicrob Agents Chemother 45: 223-228. PMID: 11120970
38. Hayama K, Ishibashi H, Ishijima SA, Niimi K, Tansho S, Ono Y, et al. (2012) A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model. FEMS microbiology letters 328: 130-137. doi: 10.1111/j.1574-6968.2011.02490.x PMID: 22211961